Compare Futu Holdings Ltd (FUTU) vs Heron Therapeutics Inc (HRTX) Price & Performance

FUTU Holdings trades at $98.13, up 1.85% with a bullish technical signal despite mixed earnings. The company shows strong fundamentals with 2025 revenue of $22.85B and net income of $11.34B, supported by robust profitability margins. However, recent quarterly earnings misses and ongoing securities class action lawsuits create significant headwinds.

While valuation metrics appear reasonable with P/E of 10.98 and analyst consensus leaning bullish (58% buy ratings), investors face substantial legal and regulatory risks. The stock's near-term trajectory will depend on Q2 2026 earnings results and resolution of multiple class action lawsuits alleging securities fraud violations.

HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.

The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.